Jeanne S Mandelblatt1, Robert A Stern2, Gheorghe Luta2, Meghan McGuckin2, Jonathan D Clapp2, Arti Hurria2, Paul B Jacobsen2, Leigh Anne Faul2, Claudine Isaacs2, Neelima Denduluri2, Brandon Gavett2, Tiffany A Traina2, Patricia Johnson2, Rebecca A Silliman2, R Scott Turner2, Darlene Howard2, John W Van Meter2, Andrew Saykin2, Tim Ahles2. 1. Jeanne S. Mandelblatt, Gheorghe Luta, Meghan McGuckin, Jonathan D. Clapp, Leigh Anne Faul, Claudine Isaacs, Neelima Denduluri, R. Scott Turner, Darlene Howard, and John W. Van Meter, Georgetown University, Washington, DC; Robert A. Stern, Brandon Gavett, Patricia Johnson, and Rebecca A. Silliman, Boston University School of Medicine, Boston, MA; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte, CA; Paul B. Jacobsen, Moffitt Cancer Center; Patricia Johnson, University of South Florida, Tampa, FL; Neelima Denduluri, Virginia Cancer Specialists, Arlington, VA; Tiffany A. Traina and Tim Ahles, Memorial Sloan-Kettering Cancer Center; Tiffany A. Traina, Weill Medical College of Cornell University, New York, NY; and Andrew Saykin, Indiana University School of Medicine, Indianapolis, IN. mandelbj@georgetown.edu. 2. Jeanne S. Mandelblatt, Gheorghe Luta, Meghan McGuckin, Jonathan D. Clapp, Leigh Anne Faul, Claudine Isaacs, Neelima Denduluri, R. Scott Turner, Darlene Howard, and John W. Van Meter, Georgetown University, Washington, DC; Robert A. Stern, Brandon Gavett, Patricia Johnson, and Rebecca A. Silliman, Boston University School of Medicine, Boston, MA; Arti Hurria, City of Hope Comprehensive Cancer Center, Duarte, CA; Paul B. Jacobsen, Moffitt Cancer Center; Patricia Johnson, University of South Florida, Tampa, FL; Neelima Denduluri, Virginia Cancer Specialists, Arlington, VA; Tiffany A. Traina and Tim Ahles, Memorial Sloan-Kettering Cancer Center; Tiffany A. Traina, Weill Medical College of Cornell University, New York, NY; and Andrew Saykin, Indiana University School of Medicine, Indianapolis, IN.
Abstract
PURPOSE: To determine if older patients with breast cancer have cognitive impairment before systemic therapy. PATIENTS AND METHODS: Participants were patients with newly diagnosed nonmetastatic breast cancer and matched friend or community controls age > 60 years without prior systemic treatment, dementia, or neurologic disease. Participants completed surveys and a 55-minute battery of 17 neuropsychological tests. Biospecimens were obtained for APOE genotyping, and clinical data were abstracted. Neuropsychological test scores were standardized using control means and standard deviations (SDs) and grouped into five domain z scores. Cognitive impairment was defined as any domain z score two SDs below or ≥ two z scores 1.5 SDs below the control mean. Multivariable analyses evaluated pretreatment differences considering age, race, education, and site; comparisons between patient cases also controlled for surgery. RESULTS: The 164 patient cases and 182 controls had similar neuropsychological domain scores. However, among patient cases, those with stage II to III cancers had lower executive function compared with those with stage 0 to I disease, after adjustment (P = .05). The odds of impairment were significantly higher among older, nonwhite, less educated women and those with greater comorbidity, after adjustment. Patient case or control status, anxiety, depression, fatigue, and surgery were not associated with impairment. However, there was an interaction between comorbidity and patient case or control status; comorbidity was strongly associated with impairment among patient cases (adjusted odds ratio, 8.77; 95% CI, 2.06 to 37.4; P = .003) but not among controls (P = .97). Only diabetes and cardiovascular disease were associated with impairment among patient cases. CONCLUSION: There were no overall differences between patients with breast cancer and controls before systemic treatment, but there may be pretreatment cognitive impairment within subgroups of patient cases with greater tumor or comorbidity burden.
PURPOSE: To determine if older patients with breast cancer have cognitive impairment before systemic therapy. PATIENTS AND METHODS: Participants were patients with newly diagnosed nonmetastatic breast cancer and matched friend or community controls age > 60 years without prior systemic treatment, dementia, or neurologic disease. Participants completed surveys and a 55-minute battery of 17 neuropsychological tests. Biospecimens were obtained for APOE genotyping, and clinical data were abstracted. Neuropsychological test scores were standardized using control means and standard deviations (SDs) and grouped into five domain z scores. Cognitive impairment was defined as any domain z score two SDs below or ≥ two z scores 1.5 SDs below the control mean. Multivariable analyses evaluated pretreatment differences considering age, race, education, and site; comparisons between patient cases also controlled for surgery. RESULTS: The 164 patient cases and 182 controls had similar neuropsychological domain scores. However, among patient cases, those with stage II to III cancers had lower executive function compared with those with stage 0 to I disease, after adjustment (P = .05). The odds of impairment were significantly higher among older, nonwhite, less educated women and those with greater comorbidity, after adjustment. Patient case or control status, anxiety, depression, fatigue, and surgery were not associated with impairment. However, there was an interaction between comorbidity and patient case or control status; comorbidity was strongly associated with impairment among patient cases (adjusted odds ratio, 8.77; 95% CI, 2.06 to 37.4; P = .003) but not among controls (P = .97). Only diabetes and cardiovascular disease were associated with impairment among patient cases. CONCLUSION: There were no overall differences between patients with breast cancer and controls before systemic treatment, but there may be pretreatment cognitive impairment within subgroups of patient cases with greater tumor or comorbidity burden.
Authors: Els Dozeman; Digna J F van Schaik; Harm W J van Marwijk; Max L Stek; Henriette E van der Horst; Aartjan T F Beekman Journal: Int J Geriatr Psychiatry Date: 2011-03 Impact factor: 3.485
Authors: S J T Jansen; W Otten; M C M Baas-Thijssen; C J H van de Velde; J W R Nortier; A M Stiggelbout Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: C M T Schilder; C Seynaeve; S C Linn; W Boogerd; L V A M Beex; C M Gundy; J W R Nortier; C J H van de Velde; F S A M van Dam; S B Schagen Journal: Psychooncology Date: 2011-02-23 Impact factor: 3.894
Authors: Brenna C McDonald; Susan K Conroy; Tim A Ahles; John D West; Andrew J Saykin Journal: Breast Cancer Res Treat Date: 2010-08-06 Impact factor: 4.872
Authors: Jeanne S Mandelblatt; Arti Hurria; Brenna C McDonald; Andrew J Saykin; Robert A Stern; John W VanMeter; Meghan McGuckin; Tiffani Traina; Neelima Denduluri; Scott Turner; Darlene Howard; Paul B Jacobsen; Tim Ahles Journal: Semin Oncol Date: 2013-12 Impact factor: 4.929
Authors: Debra E Lyon; Ronald Cohen; Huaihou Chen; Debra L Kelly; Angela Starkweather; Hyo-Chol Ahn; Colleen K Jackson-Cook Journal: J Cancer Res Clin Oncol Date: 2016-04-21 Impact factor: 4.553
Authors: Joseph M Gullett; Ronald A Cohen; Gee Su Yang; Victoria S Menzies; Robert A Fieo; Debra L Kelly; Angela R Starkweather; Colleen K Jackson-Cook; Debra E Lyon Journal: Psychooncology Date: 2019-03-14 Impact factor: 3.894
Authors: Kah Poh Loh; Michelle C Janelsins; Supriya G Mohile; Holly M Holmes; Tina Hsu; Sharon K Inouye; Meghan S Karuturi; Gretchen G Kimmick; Stuart M Lichtman; Allison Magnuson; Mary I Whitehead; Melisa L Wong; Tim A Ahles Journal: J Geriatr Oncol Date: 2016-07-05 Impact factor: 3.599